A group of Uzbekistan authors has developed and patented the technology for producing a new medicine, that have no analogues in the world. After conducting clinical trials, the drug was registered as FarGALS. The international priority for this technology was announced by the European Patent Department in 110 countries.
By its pharmaceutical properties, the drug is classified as an antiseptic and wound-healing agent. FarGALS has a wide spectrum of antimicrobial effects. It is active in respect of:
• Gram-positive and Gram-negative bacteria;
• aerobic and anaerobic, sporogenic and non-sporogenic bacteria (such as Escherichia coli, Staphylocoсcus aureus, Pseudomonas aeruginosa, Bacillus subtilis, Clostridium perfringens, Citrobacter freundii, Enterobacter agglomerans, Serratia marcescens, Morganella morganii, Acinetobacter calcoaceticus, Bacteroides fragilis, Salmonella typhi murium, Salmonella typhi, Shigella sonnei, Proteus mirabilis etc., Candida-type fungi, as well as Helicobacter pylori).
It is conducive to the improvement of vascularization in ischemic areas and has a wound-healing and anti-inflammatory effect.
Clinical trials of FarGALS
The results clinical trials showed that FarGALS may be applied as an antimicrobial agent for external use, when treating pyo-necrotic processes. The drug has a pronounced antibacterial and necrolytic effect; speeds up the cleaning of suppurating wounds and emergence of granulation tissue; reduces wound contamination; ensures a faster pace of healing; significantly better decreases the intensity of wound suppuration, swelling, hyperemia; and it has a strong local anti-inflammatory effect.
Comparison of results of the drug healing terms showed that wound healing of patients receiving FarGALS occurred two times faster than during the traditional treatment.
Antimicrobial therapy, involving the local application of FarGALS, had a positive effect on patients suffering from inflammatory diseases of mucous membranes in cervix and vagina. Comparison of results of wound healing terms in clinical trials showed that in patients with veritable cervix erosion, who were treated with this drug, granulation tissue grew 6-8 days earlier than in the control group (conventional therapy). At the same time, a high antimicrobial, analgesic and recovering effect was observed; the treatment term shortened; and indicators of bacterial vaginal smears in women with inflammatory diseases of cervix and vagina improved. No toxic and side effects associated with the application of this drug were revealed. The use of FarGALS does not have any negative influence on the scale of blood fermentation (AST, ALT), the number of leukocytes in blood and the content of protein. It does not affect blood test and urinalysis results. FarGALS has no affect blood pressure, heart contraction rate and breath rate.
How to use FarGALS
FarGALS is used in the treatment of:
• infected wounds, pyo-inflammatory skin diseases, bedsores, trophic ulcers, juvenile blackheads;
• cervicitis, colpitis, vulvovaginitis of the bacterial and mycotic etiology, and cervix erosion;
FarGALS was also tested in the military hospital. The physicians’ reports state that FarGALS is efficient for treating trophic ulcers of various genesis and pyo-necrotic processes of the diabetic etiology, suppurating and infected wounds, including suppuration of post-operation wounds in surgery. Physicians also noted that the drug is a good antimicrobial and recovering agent.
At present, FarGALS is also used in stomatology, combustiology, and otorhinolaryngology. In addition, FarGALS has been registered as a veterinary medicine.
FarGALS should be stored at room temperature. Its shelf life is two years.